Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 3/20 | 0.47 |
| ▸ | PLG | P00747 | 2/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162257 | 0.89 | DGAT1 (0.57) | PLAUNPC1RAB9ACASP3SENP7 | |
| SCHEMBL160403 | 0.83 | DGAT1 (0.56) | DGAT1 | |
| SCHEMBL158605 | 0.83 | SMN1; SMN2 (0.53) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL160613 | 0.82 | PTPN1 (0.50) | DGAT1POLBPTPN1DEGS1 | |
| SCHEMBL160317 | 0.80 | TRPV1 (0.48) | NPC1RAB9ADGAT1MEN1KMT2A | |
| SCHEMBL160629 | 0.79 | KMT2A (0.43) | NPC1RAB9ACASP3SENP7MEN1 | |
| SCHEMBL162497 | 0.78 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL162667 | 0.76 | DGAT1 (0.56) | NPC1RAB9ACASP3SENP7DGAT1 | |
| SCHEMBL159279 | 0.76 | TRPV1 (0.48) | NPC1RAB9ADGAT1MEN1KMT2A | |
| SCHEMBL158665 | 0.74 | DGAT1 (0.57) | NPC1RAB9ADGAT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | PLAU 1966/4885NPC1 86/4885RAB9A 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.